This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Atorvastatin for HAART Suboptimal Responders

This study has been completed.
Sponsor:
Collaborator:
Vaccine and Gene Therapy Institute, Florida
Information provided by (Responsible Party):
College of Health Sciences, Makerere University
ClinicalTrials.gov Identifier:
NCT01766076
First received: December 10, 2012
Last updated: May 20, 2015
Last verified: May 2015
Results First Received: July 17, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Double (Care Provider, Investigator);   Primary Purpose: Treatment
Condition: Acquired Immune Deficiency Syndrome Virus
Interventions: Other: atorvastatin, Lipitor®
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
30 participants were recruited from the Infectious Diseases Institute research cohort (single site) and followed up for 12 weeks, 4 weeks wash out period and 12 weeks after cross over of treatment assignment

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants were selected if they had sustained viral suppression for 7 years and CD4 increases below 300 cells/ul

Reporting Groups
  Description
Atorvastatin First, Then Placebo

Intervention is atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.

PBMC were collected for immune activation assays using flowcytometry

'atorvastatin, Lipitor®': PBMC collected for immune activation assays using flowcytometry

Placebo First, Then Atorvastatin

Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC were collected for immune activation assays using flowcytometry

Placebo: PBMC were collected for immune activation assays using flowcytometry


Participant Flow:   Overall Study
    Atorvastatin First, Then Placebo   Placebo First, Then Atorvastatin
STARTED   15   15 
COMPLETED   15   15 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Atorvastatin First, Then Placebo

Intervention is atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.

PBMC will be collected for immune activation assays using flowcytometry

'atorvastatin, Lipitor®': PBMC were collected for immune activation assays using flowcytometry

Placebo First, Then Atorvastatin

Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry

Placebo: PBMC were collected for immune activation assays using flowcytometry

Total Total of all reporting groups

Baseline Measures
   Atorvastatin First, Then Placebo   Placebo First, Then Atorvastatin   Total 
Overall Participants Analyzed 
[Units: Participants]
 15   15   30 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   15   15   30 
>=65 years   0   0   0 
Age 
[Units: Years]
Median (Inter-Quartile Range)
 41 
 (40 to 50) 
 47 
 (43 to 51) 
 46 
 (40 to 51) 
Gender 
[Units: Participants]
     
Female   7   10   17 
Male   8   5   13 
Region of Enrollment 
[Units: Participants]
     
Uganda   15   15   30 
CD4 T-cell activation 
[Units: Percenatage of activated CD4 T-cells]
Median (Inter-Quartile Range)
 4.2 
 (3.7 to 6.2) 
 2.9 
 (2.9 to 5.0) 
 4.2 
 (1.5 to 8.3) 


  Outcome Measures

1.  Primary:   Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily   [ Time Frame: 12 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.